Argentum is a generic drug company with core competencies in intellectual property and pharmaceutical operations. By working with branded and generic pharmaceutical companies and healthcare payors we intend to reduce the overall cost of prescription drugs by challenging patents that are not innovative and which artificially support high drug prices.
We will utilize the following strategies to reduce the overall cost of prescription drugs:
- Seek review of pharmaceutical patents that lack any true innovative contribution and which artificially support high drug prices;
- Acquire, develop and market new generic drugs; and
- Secure financial concessions on branded drugs to benefit consumers and payors.
Our operating experience is drawn from working in and with small, mid-size and large multinational pharmaceutical companies. Our innovative management team has a deep understanding of all facets of the pharmaceutical marketplace. We are dedicated to applying our expertise to reduce drug prices for consumers by challenging potentially invalid pharmaceutical patents that burden the healthcare system.
Argentum has a unique understanding of the strategic use of intellectual property, including how some companies build “artificial” IP estates to extend exclusivity of a drug franchise while offering little innovation or additional benefit to society. We believe this is an abuse of the patent system as well as the healthcare payor system.
Argentum respects the rights of innovators in the pharmaceutical industry. We believe in true innovation and the foundational patents protecting novel branded drugs. We are not “anti-patent,” but rather advocates for strong patents, supported by true innovation.